Novo Nordisk and Eli Lilly struggle to supply sought-after drugs

Massive demand for the firms’ GLP-1 drugs means providing a sufficient supply is a challenge for both Novo Nordisk and Eli Lilly.

Novo Nordisk and its US-based competitor Eli Lilly have been experiencing huge demand for their GLP-1 analogs used to treat diabetes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs